|
CEL-SCI Corporation (CVM) DCF Valuation
US | Healthcare | Biotechnology | AMEX
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
CEL-SCI Corporation (CVM) Bundle
Looking to assess CEL-SCI Corporation's intrinsic value? Our CVM DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and enhance your investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .6 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -100 | 0 | 0 | 0 | -25 | -25 | -25 | -25 | -25 |
| EBITDA | -26.8 | -34.0 | -31.7 | -27.6 | -22.2 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -4801.69 | 100 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | 2.2 | .5 | 3.9 | 4.0 | 4.0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 386.59 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -29.0 | -34.5 | -35.6 | -31.5 | -26.2 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -5188.28 | 100 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 15.5 | 42.2 | 22.7 | 4.1 | 4.7 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 9.83 | 100 | 100 | 100 | 100 | 81.97 | 81.97 | 81.97 | 81.97 | 81.97 |
| Inventories | .8 | 2.0 | 2.0 | 2.2 | 1.0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 146.79 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 2.0 | 1.7 | 1.6 | 2.0 | 1.4 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 362.13 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -2.7 | -9.0 | -.7 | -.4 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -482.38 | 100 | 100 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -30.9 | -37.1 | -37.1 | -31.7 | -26.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -30.3 | -47.2 | -33.9 | -28.0 | -21.6 | -.4 | .0 | .0 | .0 | .0 |
| WACC, % | 6.94 | 6.94 | 6.94 | 6.94 | 6.94 | 6.94 | 6.94 | 6.94 | 6.94 | 6.94 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | 7 | |||||||||
| Equity Value | -7 | |||||||||
| Diluted Shares Outstanding, MM | 54 | |||||||||
| Equity Value Per Share | -0.13 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: CEL-SCI Corporation’s financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A sleek Excel model that adjusts to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for assessing projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for CEL-SCI Corporation (CVM).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to CEL-SCI Corporation (CVM).
- Customizable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates to suit CEL-SCI Corporation (CVM).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to CEL-SCI Corporation (CVM).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis of CEL-SCI Corporation (CVM).
How It Works
- Step 1: Download the Excel file.
- Step 2: Review CEL-SCI Corporation's (CVM) pre-filled financial data and forecasts.
- Step 3: Modify critical inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for CEL-SCI Corporation (CVM)?
- Accurate Data: Utilize real CEL-SCI financials for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Pre-configured calculations save you from starting from scratch.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Intuitive design and step-by-step guidance ensure accessibility for all users.
Who Should Use This Product?
- Healthcare Researchers: Explore innovative treatment methodologies and their market implications.
- Academics: Integrate advanced models into studies or lectures focused on immunotherapy.
- Investors: Evaluate your own investment strategies and assess potential outcomes for CEL-SCI Corporation (CVM).
- Market Analysts: Enhance your analysis with a customizable model tailored for biotech companies.
- Pharmaceutical Entrepreneurs: Understand how established firms like CEL-SCI Corporation (CVM) navigate the market landscape.
What the Template Contains
- Preloaded CVM Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.